A Phase 1, Open-label, Dose-escalation, Safety and Pharmacokinetic Study of CDX-1127 in Patients With Selected Refractory or Relapsed Hematologic Malignancies or Solid Tumors

Trial Profile

A Phase 1, Open-label, Dose-escalation, Safety and Pharmacokinetic Study of CDX-1127 in Patients With Selected Refractory or Relapsed Hematologic Malignancies or Solid Tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 21 Aug 2017

At a glance

  • Drugs Varlilumab (Primary)
  • Indications Adenocarcinoma; B cell lymphoma; Burkitt's lymphoma; Chronic lymphocytic leukaemia; Colorectal cancer; Malignant melanoma; Mantle-cell lymphoma; Non-small cell lung cancer; Ovarian cancer; Prostate cancer; Renal cell carcinoma; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Celldex Therapeutics Inc
  • Most Recent Events

    • 11 Aug 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
    • 02 May 2017 Results (n=56) of ealuation of patients with solid tumours, published in the Journal of Clinical Oncology
    • 05 Jan 2016 Planned End Date changed from 1 Dec 2015 to 1 Dec 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top